Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: ild who wrote (96045)	5/24/2002 11:11:37 AM
From: Michael Bakunin	Respond to of 132070

It always did seem strange that a non-invasive procedure was considered second-line to invasive surgeries. VASO seems to have bounced today thanks to that providential PR. Official version is at: biz.yahoo.com I usually dislike seeing 'stock defense' by management. On the bright side, the ease with which they generated this study reflects the utility of their patient register. My worry on the stock is not that drug-coated stents will obviate EECP, but that VASO will have to cut prices as the market for their devices expands. We'll see, I suppose. -mb